Sign in Subscribe
Diseases

Motor Neuron Disease Pipeline Insight 2025

Strategic Insights

— 2 min read

Motor neuron diseases (MNDs) are a group of progressive neurological disorders that damage motor neurons, leading to muscle weakness and loss of mobility. There is currently no cure for MNDs, and treatments can only relieve symptoms and enhance quality of life. Despite this, the disease is a significant concern, with over 180 key companies actively involved in developing more than 200 treatment therapies for Motor Neuron Disease.

DelveInsight's report, "Motor Neuron Disease Pipeline Insight, 2025," provides comprehensive insights into the pipeline landscape of Motor Neuron Disease. The report covers 180+ companies and 200+ pipeline drugs, including clinical and nonclinical stage products. It also evaluates the therapeutic assessment by product type, stage, route of administration, and molecule type.

Key Takeaways:

  • DelveInsight's Motor Neuron Disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Motor Neuron Disease treatment.
  • Key Motor Neuron Disease companies such as Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd., Transposon Therapeutics, Inc., GeneCradle Therapeutics, Verge Genomics, QurAlis Corporation, Zydus Lifesciences Limited, Ra Pharmaceuticals, Guangzhou Magpie Pharmaceuticals Co., Ltd., Scholar Rock, Inc., Spinogenix, Seelos Therapeutics, Inc., Sanofi, Hoffmann-La Roche, Revalesio Corporation, Cytokinetics, Rapa Therapeutics LLC, Q Therapeutics, Inc., PTC Therapeutics, ProJenX, NeuroSense Therapeutics Ltd., Knopp Biosciences, MediciNova, Amylyx Pharmaceuticals Inc., Neuropore Therapies Inc, NMD Pharma A/S, Supernus Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma America Inc., MaaT Pharma are evaluating new drugs for Motor Neuron Disease.
  • Promising Motor Neuron Disease pipeline therapies in various stages of development include Talditercept alfa, Pridopidine, VM202, TPN-101, GC 101, VRG 50635, QRL 201, and others.
  • The report provides insights into the key companies that are developing therapies in the Motor Neuron Disease Market.
  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Motor Neuron Disease treatment.
  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Statistics:

  • Over 180 key companies are actively involved in developing more than 200 treatment therapies for Motor Neuron Disease.
  • The Motor Neuron Disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Motor Neuron Disease treatment.
  • The report covers around 200+ products under different phases of clinical development like Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I), Pre-clinical and Discovery stage candidates, Discontinued & Inactive candidates.
  • The products have been categorized under various ROAs such as Intravenous, Subcutaneous, Oral, Intramuscular.
  • The products have been categorized under various Molecule types such as Monoclonal antibody, Small molecule, Peptide.

Sources:

  • DelveInsight's "Motor Neuron Disease Pipeline Insight, 2025" report.
  • M2 PressWIRE-July 11, 2025-: Motor Neuron Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis.
  • BrainStorm Cell Therapeutics Inc. press release, April 2025.
  • Prilenia Therapeutics press release, April 2025.
  • Seelos Therapeutics, Inc. press release, March 2025.
  • Verge Genomics press release, March 2025.
  • OrphAI Therapeutics press release, March 2025.
  • NeuroSense Therapeutics press release, February 2025.
  • Voyager Therapeutics press release, January 2025.

Read more